Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development

Autores
Garcia Fabiani, Maria Belen; Ventosa, Maria; Comba, Andrea; Candolfi, Marianela; Nicola Candia, Alejandro Javier; Alghamri, Mahmoud S.; Kadiyala, Padma; Carney, Stephen; Faisal, Syed M.; Schwendeman, Anna; Moon, James J.; Scheetz, Lindsay; Lahann, Joerg; Mauser, Ava; Lowenstein, Pedro R.; Castro, Maria Gabriela
Año de publicación
2020
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Gliomas are infiltrating brain tumors associated with high morbidity and mortality. Current standard of care includes radiation, chemotherapy and surgical resection. Today, survival rates for malignant glioma patients remain dismal and unchanged for decades. The glioma microenvironment is highly immunosuppressive and consequently this has motivated the development of immunotherapies for counteracting this condition, enabling the immune cells within the tumor microenvironment to react against this tumor.Areas covered: The authors discuss immunotherapeutic strategies for glioma in phase-I/II clinical trials and illuminate their mechanisms of action, limitations and key challenges. They also examine promising approaches under preclinical development.Expert opinion: In the last decade there has been an expansion in immune-mediated anti-cancer therapies. In the glioma field, sophisticated strategies have been successfully implemented in preclinical models. Unfortunately, clinical trials have not yet yielded consistent results for glioma patients. This could be attributed to our limited understanding of the complex immune cell infiltration and its interaction with the tumor cells, the selected time for treatment, the combination with other therapies and the route of administration of the agent. Applying these modalities to treat malignant glioma is challenging, but many new alternatives are emerging to by-pass these hurdles.
Fil: Garcia Fabiani, Maria Belen. University of Michigan; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ventosa, Maria. University of Michigan; Estados Unidos
Fil: Comba, Andrea. University of Michigan; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Nicola Candia, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Alghamri, Mahmoud S.. University of Michigan; Estados Unidos
Fil: Kadiyala, Padma. University of Michigan; Estados Unidos
Fil: Carney, Stephen. University of Michigan; Estados Unidos
Fil: Faisal, Syed M.. University of Michigan; Estados Unidos
Fil: Schwendeman, Anna. University of Michigan; Estados Unidos
Fil: Moon, James J.. University of Michigan; Estados Unidos
Fil: Scheetz, Lindsay. University of Michigan; Estados Unidos
Fil: Lahann, Joerg. University of Michigan; Estados Unidos
Fil: Mauser, Ava. University of Michigan; Estados Unidos
Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos
Fil: Castro, Maria Gabriela. University of Michigan; Estados Unidos
Materia
ANTIBODY
CAR T-CELL
CHECKPOINT INHIBITOR
DENDRITIC CELLS
GLIOMA
IMMUNOSUPPRESSION
IMMUNOTHERAPY
NANOPARTICLES
VACCINES
VIRUS
Nivel de accesibilidad
acceso embargado
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/113423
Acceder
id CONICETDig_ad2b294349b1862ac16eb4ac407226de
oai_identifier_str oai:ri.conicet.gov.ar:11336/113423
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Immunotherapy for gliomas: shedding light on progress in preclinical and clinical developmentGarcia Fabiani, Maria BelenVentosa, MariaComba, AndreaCandolfi, MarianelaNicola Candia, Alejandro JavierAlghamri, Mahmoud S.Kadiyala, PadmaCarney, StephenFaisal, Syed M.Schwendeman, AnnaMoon, James J.Scheetz, LindsayLahann, JoergMauser, AvaLowenstein, Pedro R.Castro, Maria GabrielaANTIBODYCAR T-CELLCHECKPOINT INHIBITORDENDRITIC CELLSGLIOMAIMMUNOSUPPRESSIONIMMUNOTHERAPYNANOPARTICLESVACCINESVIRUShttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Gliomas are infiltrating brain tumors associated with high morbidity and mortality. Current standard of care includes radiation, chemotherapy and surgical resection. Today, survival rates for malignant glioma patients remain dismal and unchanged for decades. The glioma microenvironment is highly immunosuppressive and consequently this has motivated the development of immunotherapies for counteracting this condition, enabling the immune cells within the tumor microenvironment to react against this tumor.Areas covered: The authors discuss immunotherapeutic strategies for glioma in phase-I/II clinical trials and illuminate their mechanisms of action, limitations and key challenges. They also examine promising approaches under preclinical development.Expert opinion: In the last decade there has been an expansion in immune-mediated anti-cancer therapies. In the glioma field, sophisticated strategies have been successfully implemented in preclinical models. Unfortunately, clinical trials have not yet yielded consistent results for glioma patients. This could be attributed to our limited understanding of the complex immune cell infiltration and its interaction with the tumor cells, the selected time for treatment, the combination with other therapies and the route of administration of the agent. Applying these modalities to treat malignant glioma is challenging, but many new alternatives are emerging to by-pass these hurdles.Fil: Garcia Fabiani, Maria Belen. University of Michigan; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Ventosa, Maria. University of Michigan; Estados UnidosFil: Comba, Andrea. University of Michigan; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; ArgentinaFil: Nicola Candia, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; ArgentinaFil: Alghamri, Mahmoud S.. University of Michigan; Estados UnidosFil: Kadiyala, Padma. University of Michigan; Estados UnidosFil: Carney, Stephen. University of Michigan; Estados UnidosFil: Faisal, Syed M.. University of Michigan; Estados UnidosFil: Schwendeman, Anna. University of Michigan; Estados UnidosFil: Moon, James J.. University of Michigan; Estados UnidosFil: Scheetz, Lindsay. University of Michigan; Estados UnidosFil: Lahann, Joerg. University of Michigan; Estados UnidosFil: Mauser, Ava. University of Michigan; Estados UnidosFil: Lowenstein, Pedro R.. University of Michigan; Estados UnidosFil: Castro, Maria Gabriela. University of Michigan; Estados UnidosTaylor & Francis2020-06info:eu-repo/date/embargoEnd/2021-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/113423Garcia Fabiani, Maria Belen; Ventosa, Maria; Comba, Andrea; Candolfi, Marianela; Nicola Candia, Alejandro Javier; et al.; Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development; Taylor & Francis; Expert Opinion on Investigational Drugs; 4; 6-2020; 1-261354-37841744-7658CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1768528info:eu-repo/semantics/altIdentifier/doi/10.1080/13543784.2020.1768528info:eu-repo/semantics/embargoedAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:09:53Zoai:ri.conicet.gov.ar:11336/113423instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:09:54.104CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
title Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
spellingShingle Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
Garcia Fabiani, Maria Belen
ANTIBODY
CAR T-CELL
CHECKPOINT INHIBITOR
DENDRITIC CELLS
GLIOMA
IMMUNOSUPPRESSION
IMMUNOTHERAPY
NANOPARTICLES
VACCINES
VIRUS
title_short Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
title_full Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
title_fullStr Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
title_full_unstemmed Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
title_sort Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
dc.creator.none.fl_str_mv Garcia Fabiani, Maria Belen
Ventosa, Maria
Comba, Andrea
Candolfi, Marianela
Nicola Candia, Alejandro Javier
Alghamri, Mahmoud S.
Kadiyala, Padma
Carney, Stephen
Faisal, Syed M.
Schwendeman, Anna
Moon, James J.
Scheetz, Lindsay
Lahann, Joerg
Mauser, Ava
Lowenstein, Pedro R.
Castro, Maria Gabriela
author Garcia Fabiani, Maria Belen
author_facet Garcia Fabiani, Maria Belen
Ventosa, Maria
Comba, Andrea
Candolfi, Marianela
Nicola Candia, Alejandro Javier
Alghamri, Mahmoud S.
Kadiyala, Padma
Carney, Stephen
Faisal, Syed M.
Schwendeman, Anna
Moon, James J.
Scheetz, Lindsay
Lahann, Joerg
Mauser, Ava
Lowenstein, Pedro R.
Castro, Maria Gabriela
author_role author
author2 Ventosa, Maria
Comba, Andrea
Candolfi, Marianela
Nicola Candia, Alejandro Javier
Alghamri, Mahmoud S.
Kadiyala, Padma
Carney, Stephen
Faisal, Syed M.
Schwendeman, Anna
Moon, James J.
Scheetz, Lindsay
Lahann, Joerg
Mauser, Ava
Lowenstein, Pedro R.
Castro, Maria Gabriela
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv ANTIBODY
CAR T-CELL
CHECKPOINT INHIBITOR
DENDRITIC CELLS
GLIOMA
IMMUNOSUPPRESSION
IMMUNOTHERAPY
NANOPARTICLES
VACCINES
VIRUS
topic ANTIBODY
CAR T-CELL
CHECKPOINT INHIBITOR
DENDRITIC CELLS
GLIOMA
IMMUNOSUPPRESSION
IMMUNOTHERAPY
NANOPARTICLES
VACCINES
VIRUS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Gliomas are infiltrating brain tumors associated with high morbidity and mortality. Current standard of care includes radiation, chemotherapy and surgical resection. Today, survival rates for malignant glioma patients remain dismal and unchanged for decades. The glioma microenvironment is highly immunosuppressive and consequently this has motivated the development of immunotherapies for counteracting this condition, enabling the immune cells within the tumor microenvironment to react against this tumor.Areas covered: The authors discuss immunotherapeutic strategies for glioma in phase-I/II clinical trials and illuminate their mechanisms of action, limitations and key challenges. They also examine promising approaches under preclinical development.Expert opinion: In the last decade there has been an expansion in immune-mediated anti-cancer therapies. In the glioma field, sophisticated strategies have been successfully implemented in preclinical models. Unfortunately, clinical trials have not yet yielded consistent results for glioma patients. This could be attributed to our limited understanding of the complex immune cell infiltration and its interaction with the tumor cells, the selected time for treatment, the combination with other therapies and the route of administration of the agent. Applying these modalities to treat malignant glioma is challenging, but many new alternatives are emerging to by-pass these hurdles.
Fil: Garcia Fabiani, Maria Belen. University of Michigan; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ventosa, Maria. University of Michigan; Estados Unidos
Fil: Comba, Andrea. University of Michigan; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Nicola Candia, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Alghamri, Mahmoud S.. University of Michigan; Estados Unidos
Fil: Kadiyala, Padma. University of Michigan; Estados Unidos
Fil: Carney, Stephen. University of Michigan; Estados Unidos
Fil: Faisal, Syed M.. University of Michigan; Estados Unidos
Fil: Schwendeman, Anna. University of Michigan; Estados Unidos
Fil: Moon, James J.. University of Michigan; Estados Unidos
Fil: Scheetz, Lindsay. University of Michigan; Estados Unidos
Fil: Lahann, Joerg. University of Michigan; Estados Unidos
Fil: Mauser, Ava. University of Michigan; Estados Unidos
Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos
Fil: Castro, Maria Gabriela. University of Michigan; Estados Unidos
description Gliomas are infiltrating brain tumors associated with high morbidity and mortality. Current standard of care includes radiation, chemotherapy and surgical resection. Today, survival rates for malignant glioma patients remain dismal and unchanged for decades. The glioma microenvironment is highly immunosuppressive and consequently this has motivated the development of immunotherapies for counteracting this condition, enabling the immune cells within the tumor microenvironment to react against this tumor.Areas covered: The authors discuss immunotherapeutic strategies for glioma in phase-I/II clinical trials and illuminate their mechanisms of action, limitations and key challenges. They also examine promising approaches under preclinical development.Expert opinion: In the last decade there has been an expansion in immune-mediated anti-cancer therapies. In the glioma field, sophisticated strategies have been successfully implemented in preclinical models. Unfortunately, clinical trials have not yet yielded consistent results for glioma patients. This could be attributed to our limited understanding of the complex immune cell infiltration and its interaction with the tumor cells, the selected time for treatment, the combination with other therapies and the route of administration of the agent. Applying these modalities to treat malignant glioma is challenging, but many new alternatives are emerging to by-pass these hurdles.
publishDate 2020
dc.date.none.fl_str_mv 2020-06
info:eu-repo/date/embargoEnd/2021-01-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/113423
Garcia Fabiani, Maria Belen; Ventosa, Maria; Comba, Andrea; Candolfi, Marianela; Nicola Candia, Alejandro Javier; et al.; Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development; Taylor & Francis; Expert Opinion on Investigational Drugs; 4; 6-2020; 1-26
1354-3784
1744-7658
CONICET Digital
CONICET
url http://hdl.handle.net/11336/113423
identifier_str_mv Garcia Fabiani, Maria Belen; Ventosa, Maria; Comba, Andrea; Candolfi, Marianela; Nicola Candia, Alejandro Javier; et al.; Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development; Taylor & Francis; Expert Opinion on Investigational Drugs; 4; 6-2020; 1-26
1354-3784
1744-7658
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1768528
info:eu-repo/semantics/altIdentifier/doi/10.1080/13543784.2020.1768528
dc.rights.none.fl_str_mv info:eu-repo/semantics/embargoedAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv embargoedAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083247068413952
score 13.22299

Publicaciones similares